SCHEMBL27218955

SCHEMBL27218955

Cc1cc(-c2ccccc2)nc(SCc2nc(-c3ccc4c(c3)OCO4)no2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.51
RAB9A P51151 7/20 0.51
SMN1; SMN2 Q16637 6/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
PKM P14618 1/20 0.51
TDP1 Q9NUW8 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
GAA P10253 1/20 0.49
VCP P55072 1/20 0.47
LMNA P02545 2/20 0.47
HTT P42858 2/20 0.47
TSHR P16473 3/20 0.47
MAPT P10636 3/20 0.47
MAPK1 P28482 2/20 0.47
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
ALDH1A1 P00352 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31494458 0.90 RAB9A (0.54) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL27218815 0.85 RAB9A (0.49) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL27218761 0.85 RAB9A (0.64) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL31494372 0.81 SMN1; SMN2 (0.49) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL27218781 0.81 NPC1 (0.54) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL31494422 0.79 RAB9A (0.55) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL27218787 0.79 RAB9A (0.54) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL27218887 0.78 RAB9A (0.55) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL31494362 0.78 GAA (0.51) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL31494420 0.78 GAA (0.48) NPC1RAB9ASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 NPC1 781/4885RAB9A 2474/4885SMN1; SMN2 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.